ID   ATF1_HUMAN              Reviewed;         271 AA.
AC   P18846; B4DRF9; P25168; Q9H4A8;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 2.
DT   07-APR-2021, entry version 204.
DE   RecName: Full=Cyclic AMP-dependent transcription factor ATF-1;
DE            Short=cAMP-dependent transcription factor ATF-1;
DE   AltName: Full=Activating transcription factor 1;
DE   AltName: Full=Protein TREB36;
GN   Name=ATF1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2196176; DOI=10.1002/j.1460-2075.1990.tb07434.x;
RA   Yoshimura T., Fujisawa J., Yoshida M.;
RT   "Multiple cDNA clones encoding nuclear proteins that bind to the tax-
RT   dependent enhancer of HTLV-1: all contain a leucine zipper structure and
RT   basic amino acid domain.";
RL   EMBO J. 9:2537-2542(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1655749;
RA   Rehfuss R.P., Walton K.M., Loriaux M.M., Goodman R.H.;
RT   "The cAMP-regulated enhancer-binding protein ATF-1 activates transcription
RT   in response to cAMP-dependent protein kinase A.";
RL   J. Biol. Chem. 266:18431-18434(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C.,
RA   Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R.,
RA   Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E.,
RA   Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y.,
RA   Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G.,
RA   Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H.,
RA   Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S.,
RA   Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M.,
RA   Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H.,
RA   Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q.,
RA   Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V.,
RA   Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E.,
RA   Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R.,
RA   David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E.,
RA   D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N.,
RA   Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N.,
RA   Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R.,
RA   Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S.,
RA   LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H.,
RA   Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P.,
RA   Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G.,
RA   Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E.,
RA   Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S.,
RA   Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O.,
RA   Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y.,
RA   Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A.,
RA   Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F.,
RA   Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L.,
RA   Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G.,
RA   Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Bone marrow;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 39-271 (ISOFORM 1).
RX   PubMed=2516827; DOI=10.1101/gad.3.12b.2083;
RA   Hai T., Liu F., Coukos W.J., Green M.R.;
RT   "Transcription factor ATF cDNA clones: an extensive family of leucine
RT   zipper proteins able to selectively form DNA-binding heterodimers.";
RL   Genes Dev. 3:2083-2090(1989).
RN   [7]
RP   ERRATUM OF PUBMED:2516827.
RA   Hai T., Liu F., Coukos W.J., Green M.R.;
RL   Genes Dev. 4:682-682(1990).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 22-246 (ISOFORM 1), CHROMOSOMAL TRANSLOCATION
RP   WITH FUS, AND ASSOCIATION WITH ANGIOMATOID FIBROUS HISTIOCYTOMA.
RX   PubMed=11063792; DOI=10.1016/s0165-4608(00)00237-5;
RA   Waters B.L., Panagopoulos I., Allen E.F.;
RT   "Genetic characterization of angiomatoid fibrous histiocytoma identifies
RT   fusion of the FUS and ATF-1 genes induced by a chromosomal translocation
RT   involving bands 12q13 and 16p11.";
RL   Cancer Genet. Cytogenet. 121:109-116(2000).
RN   [9]
RP   PHOSPHORYLATION AT SER-63, AND PHOSPHORYLATION BY CAMK1.
RX   PubMed=8621702; DOI=10.1074/jbc.271.6.3066;
RA   Sun P., Lou L., Maurer R.A.;
RT   "Regulation of activating transcription factor-1 and the cAMP response
RT   element-binding protein by Ca2+/calmodulin-dependent protein kinases type
RT   I, II, and IV.";
RL   J. Biol. Chem. 271:3066-3073(1996).
RN   [10]
RP   CHROMOSOMAL TRANSLOCATION WITH EWSR1, AND ASSOCIATION WITH ANGIOMATOID
RP   FIBROUS HISTIOCYTOMA.
RX   PubMed=15884099; DOI=10.1002/gcc.20201;
RA   Hallor K.H., Mertens F., Jin Y., Meis-Kindblom J.M., Kindblom L.-G.,
RA   Behrendtz M., Kalen A., Mandahl N., Panagopoulos I.;
RT   "Fusion of the EWSR1 and ATF1 genes without expression of the MITF-M
RT   transcript in angiomatoid fibrous histiocytoma.";
RL   Genes Chromosomes Cancer 44:97-102(2005).
RN   [11]
RP   FUNCTION, PHOSPHORYLATION AT SER-63 BY CDK3, INTERACTION WITH CDK3, AND
RP   MUTAGENESIS OF SER-63.
RX   PubMed=18794154; DOI=10.1158/0008-5472.can-08-1137;
RA   Zheng D., Cho Y.-Y., Lau A.T.Y., Zhang J., Ma W.-Y., Bode A.M., Dong Z.;
RT   "Cyclin-dependent kinase 3-mediated activating transcription factor 1
RT   phosphorylation enhances cell transformation.";
RL   Cancer Res. 68:7650-7660(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-198, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-198, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [14]
RP   FUNCTION AS REPRESSOR, PHOSPHORYLATION AT SER-198 BY HIPK2, AND INTERACTION
RP   WITH HIPK2.
RX   PubMed=20980392; DOI=10.1242/jcs.073627;
RA   Hailemariam K., Iwasaki K., Huang B.W., Sakamoto K., Tsuji Y.;
RT   "Transcriptional regulation of ferritin and antioxidant genes by HIPK2
RT   under genotoxic stress.";
RL   J. Cell Sci. 123:3863-3871(2010).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-198, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-208 AND LYS-215, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   -!- FUNCTION: This protein binds the cAMP response element (CRE)
CC       (consensus: 5'-GTGACGT[AC][AG]-3'), a sequence present in many viral
CC       and cellular promoters. Binds to the Tax-responsive element (TRE) of
CC       HTLV-I. Mediates PKA-induced stimulation of CRE-reporter genes.
CC       Represses the expression of FTH1 and other antioxidant detoxification
CC       genes. Triggers cell proliferation and transformation.
CC       {ECO:0000269|PubMed:18794154, ECO:0000269|PubMed:20980392}.
CC   -!- SUBUNIT: Binds DNA as a dimer. Interacts with HIPK2 and CDK3.
CC       {ECO:0000269|PubMed:18794154, ECO:0000269|PubMed:20980392}.
CC   -!- INTERACTION:
CC       P18846; P18846: ATF1; NbExp=2; IntAct=EBI-852794, EBI-852794;
CC       P18846; P16220: CREB1; NbExp=6; IntAct=EBI-852794, EBI-711855;
CC       P18846; P03372: ESR1; NbExp=3; IntAct=EBI-852794, EBI-78473;
CC       P18846; P05412: JUN; NbExp=2; IntAct=EBI-852794, EBI-852823;
CC       P18846; O95644: NFATC1; NbExp=3; IntAct=EBI-852794, EBI-6907210;
CC       P18846; Q16649: NFIL3; NbExp=3; IntAct=EBI-852794, EBI-3951858;
CC       P18846; P0C746: HBZ; Xeno; NbExp=2; IntAct=EBI-852794, EBI-10890294;
CC       P18846; Q9DGW5: MDV005; Xeno; NbExp=2; IntAct=EBI-852794, EBI-10889526;
CC       P18846; P03259-2; Xeno; NbExp=2; IntAct=EBI-852794, EBI-7225021;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P18846-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P18846-2; Sequence=VSP_055559;
CC   -!- PTM: Phosphorylated at Ser-198 by HIPK2 in response to genotoxic
CC       stress. This phosphorylation promotes transcription repression of FTH1
CC       and other antioxidant detoxification genes. The CDK3-mediated
CC       phosphorylation at Ser-63 promotes its transactivation and
CC       transcriptional activities. Phosphorylated at Ser-63 by RPS6KA4 and
CC       RPS6KA5 in response to mitogenic or stress stimuli.
CC       {ECO:0000269|PubMed:18794154, ECO:0000269|PubMed:20980392,
CC       ECO:0000269|PubMed:8621702}.
CC   -!- DISEASE: Angiomatoid fibrous histiocytoma (AFH) [MIM:612160]: A
CC       distinct variant of malignant fibrous histiocytoma that typically
CC       occurs in children and adolescents and is manifest by nodular
CC       subcutaneous growth. Characteristic microscopic features include
CC       lobulated sheets of histiocyte-like cells intimately associated with
CC       areas of hemorrhage and cystic pseudovascular spaces, as well as a
CC       striking cuffing of inflammatory cells, mimicking a lymph node
CC       metastasis. Note=The gene represented in this entry may be involved in
CC       disease pathogenesis. Chromosomal aberrations involving ATF1 are found
CC       in patients with angiomatoid fibrous histiocytoma. Translocation
CC       t(12;16)(q13;p11.2) with FUS generates a chimeric ATF1/FUS protein.
CC       Translocation t(12;22)(q13;q12) with EWSR1 generates a chimeric
CC       ATF1/EWSR1 protein.
CC   -!- SIMILARITY: Belongs to the bZIP family. ATF subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAC15058.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ATF1ID81.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X55544; CAA39150.1; -; Genomic_DNA.
DR   EMBL; AK299240; BAG61271.1; -; mRNA.
DR   EMBL; AC013244; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC029619; AAH29619.1; -; mRNA.
DR   EMBL; AJ295163; CAC15058.1; ALT_INIT; mRNA.
DR   CCDS; CCDS8803.1; -. [P18846-1]
DR   PIR; S12560; S12560.
DR   RefSeq; NP_005162.1; NM_005171.4. [P18846-1]
DR   RefSeq; XP_011536688.1; XM_011538386.2. [P18846-1]
DR   RefSeq; XP_011536689.1; XM_011538387.2. [P18846-1]
DR   RefSeq; XP_016874821.1; XM_017019332.1. [P18846-1]
DR   RefSeq; XP_016874822.1; XM_017019333.1. [P18846-1]
DR   RefSeq; XP_016874823.1; XM_017019334.1. [P18846-1]
DR   SMR; P18846; -.
DR   BioGRID; 106956; 35.
DR   ComplexPortal; CPX-9; ATF1-ATF4 transcription factor complex.
DR   DIP; DIP-652N; -.
DR   IntAct; P18846; 25.
DR   MINT; P18846; -.
DR   STRING; 9606.ENSP00000262053; -.
DR   BindingDB; P18846; -.
DR   ChEMBL; CHEMBL3255; -.
DR   DrugBank; DB00852; Pseudoephedrine.
DR   GlyGen; P18846; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P18846; -.
DR   PhosphoSitePlus; P18846; -.
DR   BioMuta; ATF1; -.
DR   DMDM; 1168542; -.
DR   EPD; P18846; -.
DR   jPOST; P18846; -.
DR   MassIVE; P18846; -.
DR   MaxQB; P18846; -.
DR   PaxDb; P18846; -.
DR   PeptideAtlas; P18846; -.
DR   PRIDE; P18846; -.
DR   ProteomicsDB; 4950; -.
DR   ProteomicsDB; 53610; -. [P18846-1]
DR   ABCD; P18846; 1 sequenced antibody.
DR   Antibodypedia; 4260; 652 antibodies.
DR   DNASU; 466; -.
DR   Ensembl; ENST00000262053; ENSP00000262053; ENSG00000123268. [P18846-1]
DR   GeneID; 466; -.
DR   KEGG; hsa:466; -.
DR   UCSC; uc001rww.5; human. [P18846-1]
DR   CTD; 466; -.
DR   DisGeNET; 466; -.
DR   GeneCards; ATF1; -.
DR   HGNC; HGNC:783; ATF1.
DR   HPA; ENSG00000123268; Low tissue specificity.
DR   MalaCards; ATF1; -.
DR   MIM; 123803; gene.
DR   MIM; 612160; phenotype.
DR   neXtProt; NX_P18846; -.
DR   OpenTargets; ENSG00000123268; -.
DR   Orphanet; 97338; Melanoma of soft tissue.
DR   PharmGKB; PA25083; -.
DR   VEuPathDB; HostDB:ENSG00000123268.8; -.
DR   eggNOG; KOG3584; Eukaryota.
DR   GeneTree; ENSGT00940000158200; -.
DR   HOGENOM; CLU_042675_1_0_1; -.
DR   InParanoid; P18846; -.
DR   OMA; IGHQMSL; -.
DR   OrthoDB; 957343at2759; -.
DR   PhylomeDB; P18846; -.
DR   TreeFam; TF106464; -.
DR   PathwayCommons; P18846; -.
DR   Reactome; R-HSA-199920; CREB phosphorylation.
DR   Reactome; R-HSA-9031628; NGF-stimulated transcription.
DR   SignaLink; P18846; -.
DR   SIGNOR; P18846; -.
DR   BioGRID-ORCS; 466; 24 hits in 1015 CRISPR screens.
DR   ChiTaRS; ATF1; human.
DR   GeneWiki; ATF1; -.
DR   GenomeRNAi; 466; -.
DR   Pharos; P18846; Tchem.
DR   PRO; PR:P18846; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; P18846; protein.
DR   Bgee; ENSG00000123268; Expressed in biceps brachii and 243 other tissues.
DR   ExpressionAtlas; P18846; baseline and differential.
DR   Genevisible; P18846; HS.
DR   GO; GO:1990590; C:ATF1-ATF4 transcription factor complex; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1990589; C:ATF4-CREB1 transcription factor complex; IBA:GO_Central.
DR   GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0005667; C:transcription regulator complex; IBA:GO_Central.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; TAS:ProtInc.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046982; F:protein heterodimerization activity; IEA:InterPro.
DR   GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0034622; P:cellular protein-containing complex assembly; IEA:Ensembl.
DR   GO; GO:0045740; P:positive regulation of DNA replication; IEA:Ensembl.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:NTNU_SB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0032025; P:response to cobalt ion; IEA:Ensembl.
DR   GO; GO:0014070; P:response to organic cyclic compound; IEA:Ensembl.
DR   InterPro; IPR029825; ATF1.
DR   InterPro; IPR004827; bZIP.
DR   InterPro; IPR003102; Coactivator_CBP_pKID.
DR   InterPro; IPR001630; Leuzip_CREB.
DR   PANTHER; PTHR45879; PTHR45879; 1.
DR   PANTHER; PTHR45879:SF2; PTHR45879:SF2; 1.
DR   Pfam; PF00170; bZIP_1; 1.
DR   Pfam; PF02173; pKID; 1.
DR   SMART; SM00338; BRLZ; 1.
DR   PROSITE; PS50217; BZIP; 1.
DR   PROSITE; PS00036; BZIP_BASIC; 1.
DR   PROSITE; PS50953; KID; 1.
PE   1: Evidence at protein level;
KW   Activator; Alternative splicing; Chromosomal rearrangement; DNA-binding;
KW   Isopeptide bond; Nucleus; Phosphoprotein; Reference proteome;
KW   Transcription; Transcription regulation; Ubl conjugation.
FT   CHAIN           1..271
FT                   /note="Cyclic AMP-dependent transcription factor ATF-1"
FT                   /id="PRO_0000076575"
FT   DOMAIN          31..90
FT                   /note="KID"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00312"
FT   DOMAIN          213..271
FT                   /note="bZIP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   REGION          215..239
FT                   /note="Basic motif"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   REGION          241..262
FT                   /note="Leucine-zipper"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   SITE            110
FT                   /note="Breakpoint for translocation to form chimeric
FT                   EWSR1/ATF1 protein"
FT   SITE            112
FT                   /note="Breakpoint for translocation to form chimeric
FT                   FUS/ATF1 protein"
FT   MOD_RES         63
FT                   /note="Phosphoserine; by CaMK1, CDK3, RPS6KA4 and RPS6KA5"
FT                   /evidence="ECO:0000305|PubMed:18794154,
FT                   ECO:0000305|PubMed:8621702"
FT   MOD_RES         198
FT                   /note="Phosphoserine; by HIPK2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00312,
FT                   ECO:0000269|PubMed:20980392, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   CROSSLNK        208
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        215
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1..135
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_055559"
FT   VARIANT         191
FT                   /note="P -> A (in dbSNP:rs2230674)"
FT                   /id="VAR_024382"
FT   MUTAGEN         63
FT                   /note="S->A: Impaired CDK3-mediated phosphorylation and
FT                   altered transactivation and transcriptional activities."
FT                   /evidence="ECO:0000269|PubMed:18794154"
FT   CONFLICT        55
FT                   /note="H -> A (in Ref. 6; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        227
FT                   /note="Missing (in Ref. 6; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   271 AA;  29233 MW;  BAFECBFFB244FCED CRC64;
     MEDSHKSTTS ETAPQPGSAV QGAHISHIAQ QVSSLSESEE SQDSSDSIGS SQKAHGILAR
     RPSYRKILKD LSSEDTRGRK GDGENSGVSA AVTSMSVPTP IYQTSSGQYI AIAPNGALQL
     ASPGTDGVQG LQTLTMTNSG STQQGTTILQ YAQTSDGQQI LVPSNQVVVQ TASGDMQTYQ
     IRTTPSATSL PQTVVMTSPV TLTSQTTKTD DPQLKREIRL MKNREAAREC RRKKKEYVKC
     LENRVAVLEN QNKTLIEELK TLKDLYSNKS V
//
